(Q37265816)

19 August 2017

title

Outcome measures in rheumatologic clinical trials and systemic sclerosis (English)

1 reference

19 August 2017

D E Furst

1

1 reference

19 August 2017

publication date

1 October 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

47 Suppl 5

1 reference

19 August 2017

page(s)

v29-30

1 reference

OMERACT: an international initiative to improve outcome measurement in rheumatology

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEN269

Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEN269

An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEN269

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEN269

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEN269

Measuring outcomes in PAH: the gap between the measures that are used and their validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEN269

10.1093/RHEUMATOLOGY/KEN269

21 January 2018

Identifiers

DOI

1 reference

release_ir5ondh3lja6xh6pfs2q7la5se

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ir5ondh3lja6xh6pfs2q7la5se

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference